JAZZ – Jazz Pharmaceuticals plc
Float Short %
9.94
Margin Of Safety %
-5
Put/Call OI Ratio
0.46
EPS Next Q Diff
-2.82
EPS Last/This Y
-0.96
EPS This/Next Y
13.63
Price
170.98
Target Price
217.8
Analyst Recom
1.28
Performance Q
24.36
Relative Volume
1.02
Beta
0.26
Ticker: JAZZ
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | JAZZ | 170.53 | 0.26 | 0.96 | 13352 |
| 2025-12-29 | JAZZ | 170.57 | 0.26 | 0.17 | 13385 |
| 2025-12-30 | JAZZ | 170.73 | 0.27 | 11.12 | 13142 |
| 2025-12-31 | JAZZ | 170.02 | 0.32 | 1.65 | 13669 |
| 2026-01-02 | JAZZ | 173.07 | 0.32 | 0.16 | 13684 |
| 2026-01-05 | JAZZ | 174.43 | 0.31 | 0.17 | 14297 |
| 2026-01-06 | JAZZ | 167.02 | 0.31 | 0.04 | 14425 |
| 2026-01-07 | JAZZ | 170.03 | 0.31 | 0.98 | 14769 |
| 2026-01-08 | JAZZ | 160.27 | 0.31 | 0.93 | 14886 |
| 2026-01-09 | JAZZ | 161.19 | 0.42 | 0.13 | 16249 |
| 2026-01-12 | JAZZ | 163.71 | 0.40 | 9.70 | 16605 |
| 2026-01-13 | JAZZ | 162.5 | 0.39 | 8.77 | 16417 |
| 2026-01-14 | JAZZ | 170.8 | 0.41 | 1.82 | 16732 |
| 2026-01-15 | JAZZ | 171.15 | 0.37 | 0.03 | 16511 |
| 2026-01-16 | JAZZ | 169.33 | 0.36 | 0.05 | 17143 |
| 2026-01-20 | JAZZ | 167.99 | 0.49 | 0.29 | 8849 |
| 2026-01-21 | JAZZ | 169.88 | 0.47 | 0.05 | 9767 |
| 2026-01-22 | JAZZ | 170.92 | 0.46 | 0.20 | 9824 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | JAZZ | 170.44 | -2.8 | 1720.1 | 8.10 |
| 2025-12-29 | JAZZ | 170.50 | -2.8 | 1722.1 | 8.10 |
| 2025-12-30 | JAZZ | 170.79 | -2.8 | 1723.6 | 8.10 |
| 2025-12-31 | JAZZ | 169.99 | -2.8 | 1717.5 | 8.10 |
| 2026-01-02 | JAZZ | 173.08 | -2.8 | 1738.7 | 8.10 |
| 2026-01-05 | JAZZ | 174.45 | -2.8 | 1728.9 | 8.10 |
| 2026-01-06 | JAZZ | 167.08 | -2.8 | 1683.2 | 8.10 |
| 2026-01-07 | JAZZ | 169.37 | -2.8 | 1734.8 | 8.10 |
| 2026-01-08 | JAZZ | 160.29 | -2.8 | 1672.8 | 8.10 |
| 2026-01-09 | JAZZ | 161.06 | -2.8 | 1726.6 | 8.10 |
| 2026-01-12 | JAZZ | 163.72 | -3.0 | 1736.6 | 8.10 |
| 2026-01-13 | JAZZ | 162.47 | -2.9 | 1715.3 | 8.10 |
| 2026-01-14 | JAZZ | 170.85 | -3.2 | 1769.1 | 8.10 |
| 2026-01-15 | JAZZ | 171.28 | -3.2 | 1724.6 | 8.10 |
| 2026-01-16 | JAZZ | 169.41 | -3.2 | 1712.6 | 8.10 |
| 2026-01-20 | JAZZ | 168.04 | -3.3 | 1714.6 | 8.10 |
| 2026-01-21 | JAZZ | 169.15 | -3.3 | 1728.7 | 8.10 |
| 2026-01-22 | JAZZ | 170.98 | -3.3 | 1731.9 | 8.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | JAZZ | -4.69 | -1.73 | 8.70 |
| 2025-12-29 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2025-12-30 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2025-12-31 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2026-01-02 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2026-01-05 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-06 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-07 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-08 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-09 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-12 | JAZZ | -4.68 | -1.85 | 8.70 |
| 2026-01-13 | JAZZ | -4.66 | -1.85 | 9.25 |
| 2026-01-14 | JAZZ | -4.66 | -1.85 | 9.25 |
| 2026-01-15 | JAZZ | -4.67 | -1.85 | 9.25 |
| 2026-01-16 | JAZZ | -4.67 | -1.85 | 9.25 |
| 2026-01-20 | JAZZ | -4.67 | -2.05 | 9.25 |
| 2026-01-21 | JAZZ | -4.67 | -2.05 | 9.25 |
| 2026-01-22 | JAZZ | -4.67 | -2.05 | 9.94 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.99
Avg. EPS Est. Current Quarter
6.41
Avg. EPS Est. Next Quarter
4.17
Insider Transactions
-4.67
Institutional Transactions
-2.05
Beta
0.26
Average Sales Estimate Current Quarter
1155
Average Sales Estimate Next Quarter
994
Fair Value
162.21
Quality Score
48
Growth Score
66
Sentiment Score
64
Actual DrawDown %
9.5
Max Drawdown 5-Year %
-47.5
Target Price
217.8
P/E
Forward P/E
7.75
PEG
1.24
P/S
2.5
P/B
2.62
P/Free Cash Flow
7.77
EPS
-6.07
Average EPS Est. Cur. Y
8.1
EPS Next Y. (Est.)
21.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-8.86
Relative Volume
1.02
Return on Equity vs Sector %
-36.6
Return on Equity vs Industry %
-20.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
1731.9
Jazz Pharmaceuticals plcSector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading
Float Short %
9.94
Margin Of Safety %
-5
Put/Call OI Ratio
0.46
EPS Next Q Diff
-2.82
EPS Last/This Y
-0.96
EPS This/Next Y
13.63
Price
170.98
Target Price
217.8
Analyst Recom
1.28
Performance Q
24.36
Relative Volume
1.02
Beta
0.26
Ticker: JAZZ
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | JAZZ | 170.53 | 0.26 | 0.96 | 13352 |
| 2025-12-29 | JAZZ | 170.57 | 0.26 | 0.17 | 13385 |
| 2025-12-30 | JAZZ | 170.73 | 0.27 | 11.12 | 13142 |
| 2025-12-31 | JAZZ | 170.02 | 0.32 | 1.65 | 13669 |
| 2026-01-02 | JAZZ | 173.07 | 0.32 | 0.16 | 13684 |
| 2026-01-05 | JAZZ | 174.43 | 0.31 | 0.17 | 14297 |
| 2026-01-06 | JAZZ | 167.02 | 0.31 | 0.04 | 14425 |
| 2026-01-07 | JAZZ | 170.03 | 0.31 | 0.98 | 14769 |
| 2026-01-08 | JAZZ | 160.27 | 0.31 | 0.93 | 14886 |
| 2026-01-09 | JAZZ | 161.19 | 0.42 | 0.13 | 16249 |
| 2026-01-12 | JAZZ | 163.71 | 0.40 | 9.70 | 16605 |
| 2026-01-13 | JAZZ | 162.5 | 0.39 | 8.77 | 16417 |
| 2026-01-14 | JAZZ | 170.8 | 0.41 | 1.82 | 16732 |
| 2026-01-15 | JAZZ | 171.15 | 0.37 | 0.03 | 16511 |
| 2026-01-16 | JAZZ | 169.33 | 0.36 | 0.05 | 17143 |
| 2026-01-20 | JAZZ | 167.99 | 0.49 | 0.29 | 8849 |
| 2026-01-21 | JAZZ | 169.88 | 0.47 | 0.05 | 9767 |
| 2026-01-22 | JAZZ | 170.92 | 0.46 | 0.20 | 9824 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | JAZZ | 170.44 | -2.8 | 1720.1 | 8.10 |
| 2025-12-29 | JAZZ | 170.50 | -2.8 | 1722.1 | 8.10 |
| 2025-12-30 | JAZZ | 170.79 | -2.8 | 1723.6 | 8.10 |
| 2025-12-31 | JAZZ | 169.99 | -2.8 | 1717.5 | 8.10 |
| 2026-01-02 | JAZZ | 173.08 | -2.8 | 1738.7 | 8.10 |
| 2026-01-05 | JAZZ | 174.45 | -2.8 | 1728.9 | 8.10 |
| 2026-01-06 | JAZZ | 167.08 | -2.8 | 1683.2 | 8.10 |
| 2026-01-07 | JAZZ | 169.37 | -2.8 | 1734.8 | 8.10 |
| 2026-01-08 | JAZZ | 160.29 | -2.8 | 1672.8 | 8.10 |
| 2026-01-09 | JAZZ | 161.06 | -2.8 | 1726.6 | 8.10 |
| 2026-01-12 | JAZZ | 163.72 | -3.0 | 1736.6 | 8.10 |
| 2026-01-13 | JAZZ | 162.47 | -2.9 | 1715.3 | 8.10 |
| 2026-01-14 | JAZZ | 170.85 | -3.2 | 1769.1 | 8.10 |
| 2026-01-15 | JAZZ | 171.28 | -3.2 | 1724.6 | 8.10 |
| 2026-01-16 | JAZZ | 169.41 | -3.2 | 1712.6 | 8.10 |
| 2026-01-20 | JAZZ | 168.04 | -3.3 | 1714.6 | 8.10 |
| 2026-01-21 | JAZZ | 169.15 | -3.3 | 1728.7 | 8.10 |
| 2026-01-22 | JAZZ | 170.98 | -3.3 | 1731.9 | 8.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | JAZZ | -4.69 | -1.73 | 8.70 |
| 2025-12-29 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2025-12-30 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2025-12-31 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2026-01-02 | JAZZ | -4.69 | -1.85 | 8.70 |
| 2026-01-05 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-06 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-07 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-08 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-09 | JAZZ | -4.66 | -1.88 | 8.70 |
| 2026-01-12 | JAZZ | -4.68 | -1.85 | 8.70 |
| 2026-01-13 | JAZZ | -4.66 | -1.85 | 9.25 |
| 2026-01-14 | JAZZ | -4.66 | -1.85 | 9.25 |
| 2026-01-15 | JAZZ | -4.67 | -1.85 | 9.25 |
| 2026-01-16 | JAZZ | -4.67 | -1.85 | 9.25 |
| 2026-01-20 | JAZZ | -4.67 | -2.05 | 9.25 |
| 2026-01-21 | JAZZ | -4.67 | -2.05 | 9.25 |
| 2026-01-22 | JAZZ | -4.67 | -2.05 | 9.94 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
6.99
Avg. EPS Est. Current Quarter
6.41
Avg. EPS Est. Next Quarter
4.17
Insider Transactions
-4.67
Institutional Transactions
-2.05
Beta
0.26
Average Sales Estimate Current Quarter
1155
Average Sales Estimate Next Quarter
994
Fair Value
162.21
Quality Score
48
Growth Score
66
Sentiment Score
64
Actual DrawDown %
9.5
Max Drawdown 5-Year %
-47.5
Target Price
217.8
P/E
Forward P/E
7.75
PEG
1.24
P/S
2.5
P/B
2.62
P/Free Cash Flow
7.77
EPS
-6.07
Average EPS Est. Cur. Y
8.1
EPS Next Y. (Est.)
21.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-8.86
Relative Volume
1.02
Return on Equity vs Sector %
-36.6
Return on Equity vs Industry %
-20.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
1731.9
Jazz Pharmaceuticals plcSector: Healthcare
Industry: Biotechnology
Employees: 2800
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
stock quote shares JAZZ – Jazz Pharmaceuticals plc Stock Price stock today
news today JAZZ – Jazz Pharmaceuticals plc stock forecast ,stock prediction 2023 2024 2025
marketwatch JAZZ – Jazz Pharmaceuticals plc yahoo finance google finance
stock history JAZZ – Jazz Pharmaceuticals plc invest stock market
stock prices JAZZ premarket after hours
ticker JAZZ fair value insiders trading